Acarbose vs Semaglutide
A side-by-side research comparison of Acarbose and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Acarbose | Semaglutide |
|---|---|---|
| Full name | Acarbose (Alpha-Glucosidase Inhibitor) | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | FDA-approved drug | FDA Approved |
| Mechanism | Inhibits intestinal alpha-glucosidase enzymes, slowing the breakdown of complex carbohydrates into glucose. This flattens post-prandial glucose and insulin excursions and shifts undigested carbohydrate to the colon, feeding beneficial short-chain-fatty-acid-producing bacteria. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | 645.6 Da | 4,114 Da |
| Half-life | ~2 hours | 7 days (168 hours) |
| Bioavailability | Very low systemic (~2%); acts locally in the gut | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | 25-100 mg per meal | 0.25 mg → titrate up to 2.4 mg |
| Frequency | With carbohydrate-containing meals | Once weekly |
| Route | Oral tablet | Subcutaneous injection |
Acarbose reported benefits
- Flattens post-meal glucose spikes
- Improves glycemic variability
- Longevity signal (ITP data)
- Feeds beneficial gut bacteria
- Modest weight support
- Minimal systemic absorption
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.